1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Phase I/II Huntington’s Data From uniQure Draw Caution On Biomarker

Clinical, Functional Data Show Improvements

 
• By Alaric DeArment

The biotech company released updated data on AMT-130 meeting functional and clinical endpoints but missing one biomarker, raising questions about durability. But uniQure downplayed concerns.

• Source: Shutterstock

Updated data from uniQure N.V.’s Phase I/II trial of the gene therapy AMT-130 in Huntington’s disease has shown further evidence of improvement on functional and clinical endpoints and the biomarker of neurofilament light chain (NfL) in the cerebral spinal fluid (CSF), but continued inconclusive results on another biomarker, mutant Huntingtin protein (mHTT), which drew caution from some analysts about durability. Still, the company suggested the measurement of mHTT in the CSF was not representative of the protein’s pharmacodynamics in the brain, citing assay limitations and the way AMT-130 is administered.

The biotech announced the updated data from 39 patients in the study on 19 December, stating that patients treated with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

DMD Plans Remain Central For Regenxbio Despite Hunter Syndrome FDA Approval Delay

 
• By Manas Mishra

All eyes will be on Regenxbio's DMD data, expected next year, as the drug developer navigates a three-month delay to its FDA approval hopes for its Hunter syndrome gene therapy.

Sarepta Will Resume US Elevidys Shipments For Ambulatory DMD Patients

 
• By Mandy Jackson

The FDA recommended removal of a voluntary hold on shipments of the gene therapy to younger patients after finding that the death of an 8-year-old boy in Brazil was unrelated to Elevidys.

More Pressure on Elevidys As The EU’s CHMP Says ‘No’

 
• By Alexandra Shimmings

Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

More from Advanced Therapies

China’s BRL Gears Up For First UCAR-T Trial In Leukemia/Lymphoma

 
• By Xu Hu

Shanghai-based BRL Medicine is building a novel pipeline led by universal CAR-Ts. Its founder talks to Scrip about the benefits of this approach, China's potential advantages in the field and challenges faced by new ventures.

Competition Weighs On Gilead’s CAR-Ts As Both See Sales Decline

 
• By Alaric DeArment

The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.